Mechanism of Action
MC1R Activation and Melanogenesis
Afamelanotide binds MC1R on melanocytes with very high affinity and selectivity. MC1R couples through Gs to increase cAMP, which activates PKA and upregulates MITF (microphthalmia-associated transcription factor). MITF drives transcription of melanogenic enzymes including tyrosinase (TYR), TRP-1, and TRP-2. These enzymes convert tyrosine to DOPA to eumelanin (brown/black pigment), increasing skin melanin content. Higher eumelanin density increases the melanin index and provides photoprotection against UV-induced DNA damage.
Photoprotection in EPP
In EPP, accumulated protoporphyrin in skin absorbs Soret band light (400-420 nm, visible light), generating singlet oxygen that damages cutaneous tissue and triggers severe pain via TRPA1/TRPV1 nociceptors. Increased skin melanin from afamelanotide competes with protoporphyrin for photon absorption, reducing singlet oxygen generation and EPP phototoxic reactions. Clinical studies show patients can increase sun exposure time from near zero to ~15-30 minutes with significantly reduced pain.
Anti-Inflammatory MC1R Effects
MC1R on macrophages, dendritic cells, and keratinocytes activates cAMP/PKA to suppress NFkB, reducing inflammatory cytokine production (TNF-alpha, IL-6, IL-1beta). These direct anti-inflammatory effects are independent of melanogenesis and contribute to afamelanotide's observed reductions in UV-induced erythema and its investigated uses in inflammatory dermatology (polymorphous light eruption, vitiligo, solar urticaria).
Research Summary
Erythropoietic Protoporphyria (FDA Approved)
Standard of CarePivotal Phase III trials (CLINUVEL ACMRD program) demonstrated afamelanotide 16 mg implant significantly increased EPP patients' pain-free sun exposure time vs. placebo (median 69.4 min/day vs. 40.8 min/day over 6 months), allowing substantive quality-of-life improvement for patients who previously could not leave their homes during daylight. FDA approval in 2019 (Scenesse) was followed by EU approval. It is the only approved EPP pharmacotherapy globally.
Vitiligo
Phase IIAfamelanotide combined with narrowband UVB phototherapy produced significantly greater repigmentation of vitiligo lesions versus NB-UVB alone in Phase II studies. The proposed mechanism: afamelanotide mobilizes melanocyte precursors from hair follicles and promotes their migration into depigmented skin, which NB-UVB then activates to produce melanin. A Phase III program for vitiligo is underway.
Neurological and Other Research
ResearchMC1R is expressed in the brain, and alpha-msh/" class="wiki-internal-link">alpha-MSH analogues including afamelanotide reduce neuroinflammation in rodent models of MS, TBI, and Parkinson disease. Central MC1R activation reduces microglial activation and astrogliosis. Afamelanotide is being investigated for solar urticaria, polymorphous light eruption, actinic prurigo, and as a photoprotection strategy for organ transplant recipients on immunosuppressants who have dramatically elevated skin cancer risk.
Calculate your Afamelanotide dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| EPP prophylaxis | 16 mg SC implant | Every 60 days during peak sun exposure season | SC implant (forearm subcutis) |
| Vitiligo (with NB-UVB) | 16 mg SC implant 2 weeks before NB-UVB series | Every 60 days during NB-UVB treatment course | SC implant |
| Pigmentation research | 0.1-10 nM in melanocyte culture | Continuous exposure 48-72h | Cell culture medium |
Implant is placed via trocar in the lower abdominal subcutaneous fat. Nausea and flushing commonly occur within 1-2 days post-implant. Skin tanning occurs within 1-2 weeks and peaks at 4-6 weeks.
Interactions
Safety Profile
Afamelanotide has an established safety profile from clinical trials and 4+ years of post-marketing use. Common effects: transient nausea (30%), flushing, fatigue within 48 hours post-implant, skin hyperpigmentation (the intended effect). No evidence of increased melanoma risk in clinical studies or post-marketing surveillance. Pigmented nevi should be monitored as with any melanocortin agonist. Headache is the next most common adverse effect. The implant delivery avoids injection-site issues; biodegradable PLGA is well-established in clinical use. Pregnancy category not established.
References
- [1]Langendonk JG, et al. Afamelanotide for erythropoietic protoporphyria. N Engl J Med. 2015;373:48-59.
- [2]Grimes PE, et al. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo. JAMA Dermatol. 2013.
- [3]Harms JH, et al. Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone. Photochem Photobiol. 2009.